ClinicalTrials.gg
CompletedNCT01536873DEAPUpdated Sep 30, 2020

Dolutegravir Expanded Access Study

An interventional study of Dolutegravir in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 74 sites in 9 countries. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-09-30.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
12 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Planned enrollment
17th of 55
200 · median 126
Started
2012
with 1 other
No phase
Only one
of the 55
Registered
9th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 17th largest by planned enrollment, is one of 2 that started in 2012, is the only one with no phase, and was the 9th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

ING114916 is an open-label, multi-center, expanded access (EAP) study

Read the detailed description

ING114916 is an open-label, multi-center EAP to allow access to patients with HIV-1 infection who have documented raltegravir or elvitegravir resistance, have limited treatment options and require dolutegravir to construct a viable anti-retroviral regimen for therapy. Patients must not be eligible for another ongoing dolutegravir clinical trial in order to participate in this EAP.

The duration of patient accrual into the study will extend until dolutegravir receives local (by country) regulatory approval.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • treatment experienced patients
  • Integrase resistance
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's planned enrollment of 200 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects greater than 18 years of age 2. Documented -1 RNA >/= 400 c/mL 3. Documented raltegravir or elvitegravir resistance 4. Inability to construct a viable background ART regimen with commercially available medications.

Exclusion criteria

-

Exclusion Criteria:

  1. Creatnine clearance \< 30ml/min via method
  2. Females who are pregnant and/or breastfeeding
  3. Patients with known integrase allergic reaction
  4. > 5 times the within one month of treatment initiation
  5. ALT > 3 times ULN and total >1.5 times ULN
  6. Evidence of severe hepatic impairment
  7. Patients eligible for, and have access to, an actively enrolling DTG Phase III clinical study
  8. Any condition or any active disease during screening, anticipated requirement for any prohibited concomitant medications -
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Interventions

  • Eligible patients will receive DTG 50 mg given orally BID

07

What researchers measure

Primary outcomes

  1. Expanded access

    To to provide access in an open label protocol program to patients who have documented RAL or ELV resistance, who have limited treatment options and who require DTG to construct a viable ARV regimen for therapy

    Time frame: Not applicable for an expanded access study

Secondary outcomes

  1. Assess adverse events

    Assess any serious adverse events (SAEs) and adverse events (AEs) that lead to the discontinuation of DTG 50 mg BID

    Time frame: Not applicable for an expanded access study

08

Study locations

74 sites
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33311, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33701, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60613, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63139, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    Bronx, New York 1057, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7215, United States
  • GSK Investigational Site
    Lancaster, Pennsylvania 17604, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75204, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Graz, A-8020, Austria
  • GSK Investigational Site
    Linz, A-4020, Austria
  • GSK Investigational Site
    Vienna, A-1140, Austria
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Liege, 4000, Belgium
  • GSK Investigational Site
    Ipanema, Rio De Janeiro 22410-906, Brazil
  • GSK Investigational Site
    Macae, Rio De Janeiro 27910-210, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 2006, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 04121-000, Brazil
  • GSK Investigational Site
    Fortaleza, 60455-610, Brazil
  • GSK Investigational Site
    Maceió, 57035-110, Brazil
  • GSK Investigational Site
    Ribeirão Preto, 14048-900, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20520-054, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20725-090, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21040-900, Brazil
  • GSK Investigational Site
    Sao Paulo, 01246-000, Brazil
  • GSK Investigational Site
    Vittoria, 29020-020, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N3Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Bordeaux cedex, 33076, France
  • GSK Investigational Site
    Le Kremlin-Bicêtre Cedex, 94275, France
  • GSK Investigational Site
    Marseille, 13274, France
  • GSK Investigational Site
    Nice, 06202, France
  • GSK Investigational Site
    Paris Cedex 10, 75475, France
  • GSK Investigational Site
    Paris Cedex 14, 75679, France
  • GSK Investigational Site
    Paris Cedex 18, 75877, France
  • GSK Investigational Site
    Paris Cedex 20, 75970, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Paris, 75015, France
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70197, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Osnabrueck, Niedersachsen 49090, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50674, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23538, Germany
  • GSK Investigational Site
    Mannheim, 68161, Germany
  • GSK Investigational Site
    Genova, Liguria 16128, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Bagno A Ripoli (FI), Toscana 50011, Italy
  • GSK Investigational Site
    Firenze, Toscana 50134, Italy
  • GSK Investigational Site
    Modena, 41124, Italy
  • GSK Investigational Site
    Venezia, 30122, Italy
  • GSK Investigational Site
    Szczecin, 71-455, Poland
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Sep 2016, 51 months.

Of 402 interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2012
First posted
Feb 22, 2012
StartActual
Jun 14, 2012
Primary completionActual
Sep 23, 2016
CompletionActual
Sep 23, 2016
Last update
Sep 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01536873
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 22, 2012
Start date
Jun 14, 2012
Primary completion
Sep 23, 2016
Completion
Sep 23, 2016
Last update
Sep 30, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion